A comprehensive study of immunology repertoires in both preoperative stage and postoperative stage in patients with colorectal cancer

Abstract

Background Colorectal cancer (CRC) is the 3rd most common cancer type in the world. The correlation between immune repertoire and prognosis of CRC has been well studied in the last decades. The diversity and stability of the immune cells can be measured by hypervariable complementarity‐determining region 3 (CDR3) segments of the T‐cell receptor (TCR). Methods In this study, we collected five healthy controls and 19 CRC patients’ peripheral blood mononuclear cells (PBMCs) in three stages, namely 1 day preoperative, 3 days’ postoperative, and 7 days’ postoperative, respectively. Simultaneously, we have also done the comparative analysis of these two different anesthesia methods, namely TIVA and CEGA. Sequencing of the TCR segments has been performed by multiplex PCR and high‐throughput next‐generation sequencing. We also analyzed the distribution of CDR3 length, highly expansion clones (HECs), TRBV, and TRBJ gene usage. Results Our result showed a significant difference between TCR CDR3 length distribution and HEC distribution between CRC patients and healthy controls. We also found that TRBV11‐2, TRBV12‐1, TRBV16, TRBV3‐2, TRBV4‐2, TRBV4‐3, TRBV5‐4, TRBV6‐8, TRBV7‐8, TRBV7‐9 and RBV11‐2, TRBV12‐1, TRBV16, TRBV3‐2, TRBV4‐2, TRBV4‐3, TRBV5‐4, TRBV6‐8, TRBV7‐8, and TRBV7‐9 usages are different between CRC patients and healthy controls. Conclusion In conclusion, CRC patients were presented with different immune repertoire in comparison with healthy controls. In this study, significant difference in TRBV and TRBJ gene usage in between case and control group could provide some potential biomarker for the diagnosis and the treatment of the patients with CRC.

Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers

“… 42 A study of the correlation between immune repertoire and CRC revealed that the usage of TRBV7.8 , TRBV7.9 , TRBJ2.2 , and TRBJ2.5 had significant difference between the patients and healthy control groups. 43 The result that these featured TCR parings could be used as a prognostic classifier ( Figure 6 ), suggests that they may have important roles in activating certain immunity responses and further affecting the recurrence of lung cancer. Certainly, more evidences are needed to support the assumption.…”

Identification of LncRNA Prognostic Markers for Ovarian Cancer by Integration of Co-expression and CeRNA Network

“…LINC00402 might also affect metastatic melanoma prognosis via the ceRNA network ( Wang L. X. et al, 2019 ). A significant difference has also been reported between colorectal cancer patients and healthy controls with regard to the immunological indicator TRBV11-2 ( Liu X. et al, 2019 ). Furthermore, TRBV11-2 is associated with CD8 + T-cell immune responses in dengue virus infection ( Culshaw et al, 2017 ).…”

T‐cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications

“…The HEC ratio is calculated as the sum of the abundance of all sequences with the abundance higher than the threshold. The common threshold is 0.01% or 0.1%, and its threshold setting can be adjusted according to research needs [3].…”

“…Liu et al . [3] investigated the changes in peripheral blood TCR repertoire before and after radical surgery in 19 colorectal cancer patients (T1M0N0, stage I). Five healthy subjects were included as controls.…”

“…Since the year 2011, there have been rapid developments in the field of immunotherapy, and a range of immunocheckpoint inhibitors (ICIs) have been approved for a range of metastatic cancers, including malignant melanoma, lung, kidney, and bladder cancers [1][2][3][4][5]. In recent years, the clinical trial results of genetically engineered immune cells, including chimeric antigen receptor T-cell (CAR-T), TCRengineered T-cell (TCR-T), chimeric antigen receptor natural killer cell (CAR-NK) and more, in the treatment of hematological tumors have also been encouraging [6][7][8].…”